Actively Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
Led by Zhejiang University · Updated on 2024-01-30
3600
Participants Needed
6
Research Sites
180 weeks
Total Duration
On this page
Sponsors
Z
Zhejiang University
Lead Sponsor
N
New Horizon Health Technology Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of the study is to screen multi-omics markers in blood samples and construct a prediction model for CRC based on liquid biopsy, and we will further optimize the prediction model by validating its clinical performance externally.
CONDITIONS
Official Title
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged over 18 years
- Confirmed colorectal adenocarcinoma or advanced adenoma through colonoscopy and pathology (case arm)
- No history of colorectal adenomas or sessile serrated polyps (general-risk control arm)
- No history of inflammatory bowel disease for 8-10 years (general-risk control arm)
- No family history of colorectal cancer in first-degree relatives (general-risk control arm)
- At least one of the following for high-risk control arm: Asia-Pacific Colorectal Screening score 4, family history of colorectal cancer in first-degree relatives, positive fecal occult blood test, two or more of chronic diarrhea, chronic constipation, mucous bloody stools, psychological stimulation, chronic appendicitis or appendectomy, chronic biliary disease or cholecystectomy
- Inflammatory bowel disease (high-risk control arm)
- Confirmed absence of colorectal malignancy or advanced adenomas via colonoscopy (control arm)
- Provision of informed consent prior to study procedures, sampling, and analyses
You will not qualify if you...
- History of other malignant tumors excluding non-melanoma skin cancer
- Prior colorectal cancer or advanced adenoma treatments including surgery, endoscopic treatment, chemotherapy, targeted therapy, immunotherapy, radiation, or neoadjuvant therapy
- Hereditary colorectal diseases such as Lynch syndrome, familial CRC type X, familial adenomatous polyposis, MUTHY-associated polyposis, Peutz-Jeghers syndrome, juvenile polyposis syndrome, or serrated polyposis syndrome
- Use of anti-tumor drugs like methotrexate, cyclophosphamide, mercaptopurine, or bendamustine within 30 days before blood collection
- Blood transfusion within 2 weeks prior to blood collection
- Prior organ, bone marrow, or stem cell transplantation
- Pregnancy
- Anti-infection treatment within 14 days before blood collection
- Inability to comply with study procedures such as blood collection and examinations
- Deemed unsuitable for clinical trial participation by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
The Second Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 31000
Actively Recruiting
2
Sun Yat-Sen University Cancer Hospital
Guangzhou, China
Actively Recruiting
3
Yunnan cancer hospital
Kunming, China
Actively Recruiting
4
Jiangsu province hospital
Nanjing, China
Actively Recruiting
5
The first affiliated hospital of Xi'an Jiaotong University
Xi'an, China
Actively Recruiting
6
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University
Zhengzhou, China
Actively Recruiting
Research Team
K
Kefeng Ding, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here